The effect of quantification standards used in real-time CMV PCR assays on guidelines for initiation of therapy in allogeneic stem cell transplant patients [1]

Bone Marrow Transplantation

Volumn 39, Issue 4, 2007, Pages 237-238

  Harrington, S M ^a   Buller, R S ^b   Storch, G A ^b   Li, L ^a   Fischer, S H ^a   Murray, P R ^a   Gea Banacloche, J C ^c  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CYTOMEGALOVIRUS ANTIGEN PP65; EDETIC ACID; GANCICLOVIR; VIRUS DNA;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CYTOMEGALOVIRUS INFECTION; DNA EXTRACTION; GRAFT RECIPIENT; HUMAN; LETTER; MOLECULAR CLONING; MORBIDITY; MORTALITY; PLASMID; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; VIREMIA; VIRUS LOAD; VIRUS REACTIVATION;

CHEMOPREVENTION; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; GANCICLOVIR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINES; REFERENCE VALUES; TRANSPLANTATION, HOMOLOGOUS;

EID: 33846981167     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705558     Document Type: Letter

References (9)

1. Boeckh M, Gallez-Hawkins G, Myerson D, Zaia J, Bowden R. Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation: Comparison with polymerase chain reaction using peripheral blood leukocytes, pp65 antigenemia, and viral culture. Transplantation 1997; 64: 108-113.
2. Solano C, Munoz I, Gutierrez A, Farga A, Prosper F, Garcia-Conde J et al. Qualitative plasma PCR assay (AMPLICOR CMV test) versus pp65 antigenemia assay for monitoring cytomegalovirus viremia and guiding preemptive ganciclovir therapy in allogeneic stem cell transplantation. J Clin Microbiol 2001; 39: 3938-3941.
3. Lengerke C, Ljubicic T, Meisner C, Loeffler J, Sinzger C, Einsele H et al. Evaluation of the COBAS Amplicor HCMV monitor for early detection and monitoring of human cytomegalovirus infection after allogeneic stem cell transplantation. Bone Marrow Transplant 2006; 38: 53-60.
4. Centers for Disease Control Prevention. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients: Recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation. MMWR 2000; 49 (No. RR-10): 1-125.
5. Mori T, Okamoto S, Watanabe R, Yajima T, Iwao Y, Yamazaki R et al. Dose-adjusted preemptive therapy for cytomegalovirus disease based on real-time polymerase chain reaction after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 29: 777-782.
6. Verkruyse L, Storch G, Devine S, Dipersio J, Vij R. Once daily ganciclovir as initial pre-emptive therapy delayed until threshold CMV load > or = 10 000 copies/ml: A safe and effective strategy for allogeneic stem cell transplant patients. Bone Marrow Transplant 2006; 37: 51-56.
7. Qamruddin A, Oppenheim B, Guiver M, Mutton K, Chopra R. Screening for cytomegalovirus (CMV) infection in allogeneic bone marrow transplantation using a quantitative whole blood polymerase chain reaction (PCR) method: Analysis of potential risk factors for CMV infection. Bone Marrow Transplant 2001; 27: 301-306.
8. Cortez K, Fischer SH, Fahle GA, Calhoun LB, Childs RW, Barrett AJ et al. Clinical trial of quantitative real-time polymerase chain reaction for detection of cytomegalovirus in peripheral blood of allogeneic hematopoietic stem-cell transplant recipients. J Infect Dis 2003; 188: 967-972.
9. Sanchez J, Storch G. Multiplex, quantitative, real-time PCR assay for cytomegalovirus and human DNA. J Clin Microbiol 2002; 40: 2381-2386.